Guanidinium-based Integrated Peptide Dendrimers: Pioneer Nanocarrier in Cancer Therapy

Author:

Singh Dilpreet12,Muhammad Irham Lalu3,Singh Amrinder4,Kurmi Balak Das5

Affiliation:

1. University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali, 140413, India

2. University Centre for Research and Development, Chandigarh University, Gharuan (140413), India

3. Pharmacy of Faculty, University of Ahmad Dahlan, Yogyakarta, Indonesia

4. Chitkara College of Pharmacy, Chitkara University, Punjab, India

5. Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, 142001, India

Abstract

Abstract: The landscape of cancer therapy has witnessed a paradigm shift with the emergence of innovative delivery systems, and Guanidinium-based Peptide Dendrimers have emerged as a vanguard in this transformative journey. With their unique molecular architecture and intrinsic biocompatibility, these dendrimers offer a promising avenue for the targeted delivery of therapeutic cargo in cancer treatment. This comprehensive review delves into the intricate world of Guanidinium- based Peptide Dendrimers, unraveling their structural intricacies, mechanisms of action, and advancements that have propelled them from laboratory curiosities to potential clinical champions. Exploiting the potent properties of guanidinium, these dendrimers exhibit unparalleled precision in encapsulating and transporting diverse cargo molecules, ranging from conventional chemotherapeutics to cutting-edge nucleic acids. The review navigates the depths of their design principles, investigating their prowess in traversing the complex terrain of cellular barriers for optimal cargo delivery. Moreover, it delves into emerging trends, such as personalized therapeutic approaches, multimodal imaging, and bioinformatics-driven design, highlighting their potential to redefine the future of cancer therapy. Crucially, the review addresses the pivotal concerns of biocompatibility and safety, examining cytotoxicity profiles, immune responses, and in vivo studies. It underscores the importance of aligning scientific marvels with the stringent demands of clinical applications. Through each section, the narrative underscores the promises and possibilities that Guanidinium-based Peptide Dendrimers hold and how they can potentially reshape the landscape of precision cancer therapy.

Publisher

Bentham Science Publishers Ltd.

Reference103 articles.

1. Cheng Y.; Xu T.; Guanidinium-based peptide dendrimers for drug delivery applications. Adv Drug Deliv Rev 2017,110-111,101-116

2. Misra S.K.; Moitra P.; Kondaiah P.; Bhattacharya S.; Guanidinium-based peptide dendrimers for targeted delivery of therapeutic molecules to cancer cells. J Control Release 2018,290,103-121

3. Li S.; Byrne J.D.; Kim J.; Self-assembled cationic peptide nanoparticles as an efficient antibacterial agent. Nat Nanotechnol 2011,6(12),1-8

4. Jain K.; Kesharwani P.; Gupta U.; Jain N.K.; Dendrimer toxicity: Let’s meet the challenge. Int J Pharm 2010,394(1-2),122-142

5. Dash T.K.; Konkimalla V.B.; Poly-є-caprolactone based formulations for drug delivery and tissue engineering: A review. J Control Release 2012,158(1),15-33

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3